Press Release
Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India
Sun Pharma No. 1 Generic Company in PatientView Survey
Read MoreEarnings Call
Webcast – Q4 FY22 Earnings call
Press Release
Q4 FY22 Financial Press Release
Financial Results
Q4 FY22 Financial Results
COVID-19 Response
We are committed to ensure uninterrupted supply of medicines to support the Covid-19 pandemic response
The Sun Story
Watch the inspiring growth story of Sun – from humble beginnings in 1983 with just 2 employees and 5 psychiatry products to becoming the 4th largest global generic pharmaceutical company, selling over 2000 products in over 100 countries.
Sun Pharma on Twitter
Find out more
Innovation
Science is at the heart of Sun Pharma. Our scientists work closely with doctors, patients, and business development teams, to generate innovative concepts and ideas to harness market needs and synergies across therapeutic areas.
Quality
Our vision is to globalize, harmonize and simplify GxP processes to achieve a sustainable quality culture.
Careers
We hire exceptionally talented individuals, and ensure they are nurtured professionally. Our multi-dimensional work environment offers high growth opportunities through challenging roles with clear responsibilities.
Responsibility
Our CSR efforts are focused on serving and helping needy and underprivileged communities. Our priority areas include: health, education, drinking water and sanitation.
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities or products owned or operated by Ranbaxy prior to Sun Pharma acquisition of Ranbaxy. Continue
Whistle Blower Policy for Sun Pharmaceutical Industries Limited & its Subsidiaries
Ranbaxy's Disclosure Program
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities owned or operated by Ranbaxy or products owned by Ranbaxy prior to Sun Pharma’s acquisition of Ranbaxy. This Disclosure Program (the “Ranbaxy Disclosure Program”) applies specifically to those facilities and products, and is different from the Disclosure Programs or policies that apply to other products or facilities owned or operated by Sun Pharma (links to Sun Pharma’s Whistleblower Policy appear in the box above). If you are an individual seeking to disclose issues or questions under the Ranbaxy Disclosure Program, please proceed by clicking Continue
Ranbaxy's Disclosure Policy
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities owned or operated by Ranbaxy or products owned by Ranbaxy prior to Sun Pharma’s acquisition of Ranbaxy. This Disclosure Program (the “Ranbaxy Disclosure Program”) applies specifically to those facilities and products, and is different from the Disclosure Programs or policies that apply to other products or facilities owned or operated by Sun Pharma (links to Sun Pharma’s Whistleblower Policy appear in the box above). If you are an individual seeking to disclose issues or questions under the Ranbaxy Disclosure Program, please proceed by clicking Continue